As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of BioRestorative Therapies, Inc. The largest reported stake is Auctus Fund, LLC's, at 9.9%. 8 filings are on record since August 14, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like BioRestorative Therapies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Alta Partners LLC · Sole voting: 1,338,133 · Shared voting: 0 · Sole dispositive: 1,338,133 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-03
- · Reporting person: Auctus Fund, LLC · Sole voting: 0 · Shared voting: 2,699,470 · Sole dispositive: 0 · Shared dispositive: 2,699,470 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Morrison Todd Hale · Percent: 0% · Shares: 0 · SCHEDULE 13G/A
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 922,143 · Sole dispositive: 0 · Shared dispositive: 922,143 · SCHEDULE 13G, 2026-02-18
- · Holder: Auctus Fund, LLC · Percent: 9.9% · SCHEDULE 13G/A
BioRestorative Therapies, Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Auctus Fund, LLC | 9.9% | 2,699,470 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Alta Partners LLC | 4.9% | 1,338,133 | SCHEDULE 13G/A, 2026-08-03 | 2026-02-13 |
| 4.1% | 922,143 | SCHEDULE 13G, 2026-02-18 | 2026-02-11 | |
| 0% | 0 | SCHEDULE 13G/A, 2026-02-23 | 2026-02-23 |
Holding shares or following this stake? See who's behind BioRestorative Therapies, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on BioRestorative Therapies, Inc. and the records around it.
BioRestorative Therapies, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch BioRestorative Therapies, Inc.
Get an email when BioRestorative Therapies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioRestorative Therapies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioRestorative Therapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioRestorative Therapies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Auctus Fund, LLC | 0 | 2,699,470 | 0 | 2,699,470 | SCHEDULE 13G/A, 2026-05-15 |
| Auctus Fund Management LLC | 0 | 2,699,470 | 0 | 2,699,470 | SCHEDULE 13G/A, 2026-05-15 |
| Alfred Sollami | 0 | 2,699,470 | 0 | 2,699,470 | SCHEDULE 13G/A, 2026-05-15 |
| Louis Posner | 0 | 2,699,470 | 0 | 2,699,470 | SCHEDULE 13G/A, 2026-05-15 |
| Alta Partners LLC | 1,338,133 | 0 | 1,338,133 | 0 | SCHEDULE 13G/A, 2026-08-03 |
| Mitchell P. Kopin | 0 | 922,143 | 0 | 922,143 | SCHEDULE 13G, 2026-02-18 |
| Daniel B. Asher | 0 | 922,143 | 0 | 922,143 | SCHEDULE 13G, 2026-02-18 |
| Intracoastal Capital, LLC | 0 | 922,143 | 0 | 922,143 | SCHEDULE 13G, 2026-02-18 |
| Morrison Todd Hale | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-23 |
The latest filing identifies BioRestorative Therapies, Inc. by CUSIP 090655606 and gives its principal executive office as 40 MARCUS DRIVE, MELVILLE, NY 11747 (SCHEDULE 13G/A, 2026-08-03).
What the percentages are based on
This amount comprises beneficial ownership of 2,699,470 shares of Common Stock which consists of (i) 1,155,914 shares of Common Stock and (ii) 1,543,556 shares issuable upon exercise of warrants held by Auctus Fund, LLC (the "Warrants").Auctus Fund, LLC, SCHEDULE 13G/A, 2026-05-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Auctus Fund, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-12-19 | Morrison Todd Hale | 7.7% | SCHEDULE 13G/A |
| 2026-02-13 | Alta Partners LLC | 7.7% | SCHEDULE 13G |
| 2026-02-17 | Auctus Fund, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-02-18 | Mitchell P. Kopin | 4.1% | SCHEDULE 13G |
| 2026-02-23 | Morrison Todd Hale | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Auctus Fund, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-08-03 | Alta Partners LLC | 4.9% | SCHEDULE 13G/A |
Questions about who owns BioRestorative Therapies, Inc.
Who owns BioRestorative Therapies, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of BioRestorative Therapies, Inc.: Auctus Fund, LLC (9.9%, Schedule 13G/A, filed 2026-05-15).
When did Auctus Fund, LLC buy into BioRestorative Therapies, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Auctus Fund, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%; its latest, Schedule 13G/A filed 2026-05-15, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for BioRestorative Therapies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 2, 2026 | Leadership change: Mika Grasso appointed, Chief Executive Officer, and 1 more | — | Leadership changes | Source |
| July 16, 2026 | Leadership change: David Rosa departs, Director, and 2 more | — | Leadership changes | Source |
| June 12, 2026 | Leadership change: Mika Grasso appointed, Director | — | Leadership changes | Source |
| October 9, 2025 | Form D, private offering | $1.40M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for BioRestorative Therapies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.